MX2009008874A - Metodos para identificar activadores de cinasa lyn. - Google Patents

Metodos para identificar activadores de cinasa lyn.

Info

Publication number
MX2009008874A
MX2009008874A MX2009008874A MX2009008874A MX2009008874A MX 2009008874 A MX2009008874 A MX 2009008874A MX 2009008874 A MX2009008874 A MX 2009008874A MX 2009008874 A MX2009008874 A MX 2009008874A MX 2009008874 A MX2009008874 A MX 2009008874A
Authority
MX
Mexico
Prior art keywords
lyn kinase
methods
substrate
test compound
identifying activators
Prior art date
Application number
MX2009008874A
Other languages
English (en)
Inventor
Andrew Reaume
Michael Saporito
Original Assignee
Melior Pharmaceuticals I Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melior Pharmaceuticals I Inc filed Critical Melior Pharmaceuticals I Inc
Publication of MX2009008874A publication Critical patent/MX2009008874A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a métodos para identificar activadores de cinasa Lyn al preincubar un compuesto de prueba en presencia de cinasa Lyn; añadir ATP y substrato a la cinasa Lyn y compuesto de prueba; incubar el compuesto de prueba, cinasa Lyn, ATP y substrato, y medir el nivel de fosforilación del substrato, con lo cual un incremento en el nivel de fosforilación del substrato indica que el compuesto de prueba es un activador de cinasa Lyn.
MX2009008874A 2007-02-20 2008-02-20 Metodos para identificar activadores de cinasa lyn. MX2009008874A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89063207P 2007-02-20 2007-02-20
PCT/US2008/054361 WO2008103692A2 (en) 2007-02-20 2008-02-20 Methods of identifying activators of lyn kinase

Publications (1)

Publication Number Publication Date
MX2009008874A true MX2009008874A (es) 2009-10-20

Family

ID=39710712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008874A MX2009008874A (es) 2007-02-20 2008-02-20 Metodos para identificar activadores de cinasa lyn.

Country Status (13)

Country Link
US (1) US20100152215A1 (es)
EP (1) EP2120581A4 (es)
JP (1) JP2010518860A (es)
KR (1) KR20100014480A (es)
CN (1) CN101686686A (es)
AU (1) AU2008218765A1 (es)
BR (1) BRPI0807928A2 (es)
CA (1) CA2678813A1 (es)
IL (1) IL200429A0 (es)
MX (1) MX2009008874A (es)
NZ (1) NZ579227A (es)
WO (1) WO2008103692A2 (es)
ZA (1) ZA200905776B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
CN102507707B (zh) * 2011-10-12 2015-10-21 山东大学 一种检测龈沟液中蛋白裂解酶含量的方法
US9827222B2 (en) * 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
JP6584322B2 (ja) 2013-12-27 2019-10-02 国立大学法人 東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
EP3755334A4 (en) * 2018-02-21 2022-03-23 Melior Pharmaceuticals I, Inc. TREATMENT OF LIVER DISEASES

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3922345A (en) * 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines
US4080454A (en) * 1976-07-16 1978-03-21 Pfizer Inc. 5-M-Tolyloxyuracil, anti-ulcer agent
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
US6900304B2 (en) * 1996-01-31 2005-05-31 The Regents Of The University Of California Emission ratiometric indicators of phosphorylation
US20020019346A1 (en) * 1997-05-21 2002-02-14 Children's Medical Center Corporation Treatment of prostate cancer by inhibiting lyn tyrosine kinase
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
GB0104422D0 (en) * 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US20050009817A1 (en) * 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
EP1541694A1 (en) * 2003-12-12 2005-06-15 Sirenade Pharmaceuticals AG Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase
US20060035302A1 (en) * 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
CA2587642C (en) * 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
ITUD20050112A1 (it) * 2005-07-01 2007-01-02 Gaetano Azzolina Dispositivo di assistenza cardiocircolatoria
TWI273177B (en) * 2005-07-08 2007-02-11 Ama Precision Inc Fan apparatus with adapting device
WO2007016975A1 (en) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Kinase and phosphatase assays based on fret
CA2620065C (en) * 2005-08-22 2011-03-29 Melior Discovery, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism

Also Published As

Publication number Publication date
BRPI0807928A2 (pt) 2014-07-08
ZA200905776B (en) 2010-05-26
KR20100014480A (ko) 2010-02-10
WO2008103692A2 (en) 2008-08-28
EP2120581A4 (en) 2011-03-16
AU2008218765A1 (en) 2008-08-28
NZ579227A (en) 2012-11-30
IL200429A0 (en) 2010-04-29
CA2678813A1 (en) 2008-08-28
US20100152215A1 (en) 2010-06-17
WO2008103692A3 (en) 2008-10-23
JP2010518860A (ja) 2010-06-03
EP2120581A2 (en) 2009-11-25
CN101686686A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
MX2009008874A (es) Metodos para identificar activadores de cinasa lyn.
TN2012000485A1 (en) Predictive markers useful in the treatment of fragile x syndrome (fxs)
TN2010000131A1 (en) Polo-like kinase inhibitors
MY170983A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
ZA200808536B (en) Deazapurines useful as inhibitors of janus kinases
EP2373784A4 (en) GENERATION AND MAINTENANCE OF STEM CELLS
MY160734A (en) Besylate salt of a btk inhibitor
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
MY146989A (en) Kinase inhibitors
WO2011097301A3 (en) METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
MX339811B (es) Conjugados e inhibidores de cinasa de proteina.
ZA200802685B (en) Deazapurines useful as inhibitors of janus kinases
TW200720257A (en) Pyrimidine compounds and methods of use
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
MX2009005829A (es) Polialquileniminas hidrofobicamente modificadas para usarse como inhibidores de transferencia de colorante.
CR20140128A (es) Inhibidores de la enzima activadora de nedd 8
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
MX2009012612A (es) Purinonas e inhibidores 1h-imidazopiridinonas como pkc-theta.
WO2012027266A3 (en) Methods for dectecting embryonic stem cells, induced pluripotent stem cells, or cells undergoing reprogramming to produce induced pluripotent stem cells
CY1118495T1 (el) Συνθεσεις συνδυασμου αγωνιστων α1 αδενοσινης και αναστολεων ανθρακικης ανυδρασης για μειωση της ενδοφθαλμιας πιεσης
GB201021509D0 (en) Assay method

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal